How a TTO licenses IP to a faculty or student startup: equity and deferred royalty
University startup license terms for Indian TTOs: NISP 2019 limits on royalty and equity, deferred payments, milestones and conflicts, with a worked deal.
A university licenses IP to its own startup through a written licence that defers cash. Under the National Innovation and Startup Policy 2019, royalties should be no more than 4% of sale price, preferably 1 to 2%, or the institute can take 1% to 4% of shares instead. Upfront fees are usually small or deferred until funding or sales.
A startup founded by your own faculty or students is the easiest licensee to find and the hardest to price. It wants the technology, it has the inventors, and it has almost no cash. A TTO that asks for a normal upfront fee kills the company. A TTO that gives the IP away loses the institute's return and, later, its credibility with investors who expect clean paperwork.
The answer is a licence that defers cash and ties the institute's return to the startup's success. This guide sets out the national guidance in India, the main payment tools, the clauses that protect the institute and a worked deal.
What does national policy say?
The National Innovation and Startup Policy 2019, issued by the Ministry of Education's Innovation Cell (then the MHRD), is the main guidance for higher education institutions. On licensing to startups, it says:
| Point | NISP 2019 |
|---|---|
| Licensing to startups | Institutes will allow licensing of IPR from the institute to startups |
| Royalty | No more than 4% of sale price, preferably 1 to 2%, unless pure software |
| Software | A revenue share agreed between the institute and the company |
| Shares instead of royalty | 1% to 4% |
| Incubator equity | 2% to 9.5%, for services and facilities |
| Staff and faculty founders drawing full salary | Institute can take no more than 20% of the shares the staff or faculty member takes, within the 9.5% limit |
| Technology source | Only technologies originating in the same institute for faculty startups |
NISP is guidance. Your institute's own IP and startup policy decides the actual terms, so read both. The faculty side of the same rules is covered in starting a company as a faculty member.
Which payment tools can a TTO use?
| Tool | How it works | When it suits |
|---|---|---|
| Small upfront fee | A token amount at signing | Always, to make the licence a real commercial contract |
| Deferred fee | A fixed sum due at a trigger: funding round, first sales or a date | Startup expects to raise money soon |
| Running royalty | A percentage of sales, within the NISP range | Product sales are the main value |
| Equity | Shares issued to the institute instead of, or with, royalty | Value is in the company more than the product |
| Milestone payments | Sums due on events such as regulatory approval | Long development path, such as medical devices |
| Sublicence share | A percentage of sublicensing income | Startup may license onward instead of making the product |
Most deals combine two or three. A common pattern is a small upfront fee, a deferred fee on the first funding round, and either a royalty or equity.
Royalty or equity for the institute
Royalty suits products; equity suits companies investors will grow.
How should a deferred payment be written?
A deferred payment fails when its trigger is vague. Write:
- The amount, or a formula.
- The trigger: "within 60 days of the startup receiving cumulative equity investment of ₹1 crore", or "on the first anniversary of first commercial sale".
- A long-stop date, so the payment falls due even if the trigger never happens.
- Whether it converts to equity if the startup prefers.
Without a long-stop date, a startup that never raises a formal round never pays.
What protects the institute?
An exclusive licence to a startup carries more risk than one to an established company. Build in:
- Diligence milestones: a prototype by a date, first sales by a date, funding raised by a date. See diligence obligations in exclusive licences.
- The right to convert to non-exclusive or terminate if milestones are missed.
- Patent cost terms: who pays prosecution and renewal fees, and from when.
- Assignment limits: the licence cannot pass to an acquirer without consent, or passes only with a change-of-control payment.
- Reporting: annual reports on development, funding and sales.
- Conflict of interest: NISP asks institutes to develop a conflict-of-interest policy. Inventors who are founders should not negotiate for the institute.
Put the agreement in writing with all its terms; under section 68 of the Patents Act, a patent licence is valid only if it is in writing and duly executed. An MoU will not do; see MoU or licence agreement.
Licensing to an institute startup
What happens when the startup raises money or is sold?
Investors will read the licence before they invest, and an acquirer will read it before it buys. Three clauses decide whether the licence helps or blocks those deals.
| Clause | What to agree | Why it matters |
|---|---|---|
| Change of control | The licence continues on a sale, with notice to the institute, or a payment on change of control | Acquirers need the licence to survive; the institute may want a share of the value |
| Sublicensing | Whether the startup may sublicense, and the institute's share of sublicensing income | A startup may license onward instead of making the product |
| Dilution | If the institute holds licence equity, whether it is protected in early rounds or diluted with everyone else | Small holdings shrink quickly without terms |
Keep these terms simple. A licence with heavy restrictions on sale or funding can scare away the investors the startup needs, which hurts the institute too.
Investors also check that the startup holds clean rights: that the institute owns the IP, that every inventor assigned to the institute, and that the licence covers the product they are funding. A TTO that keeps these documents ready helps its startups close rounds faster.
A worked example
Illustration with invented figures and terms. An institute licenses a water sensor patent exclusively to a startup founded by two PhD graduates and their supervisor.
| Term | Amount |
|---|---|
| Upfront fee at signing | ₹50,000 |
| Deferred fee on first funding round of ₹1 crore or more, long-stop 3 years | ₹5,00,000 |
| Running royalty | 2% of net sales |
| Equity instead of more royalty | None; incubator holds 5% separately for services |
| Year three sales | ₹2,50,00,000 |
| Royalty in year three | ₹5,00,000 |
If the startup raises its round in year two and reaches ₹2.5 crore of sales in year three, the institute receives ₹10.5 lakh over three years: ₹50,000 upfront, ₹5 lakh deferred and ₹5 lakh in royalty. If the startup stalls, the institute takes the licence back under the milestone clause and can offer the patent elsewhere. Inventor shares follow the institute's policy; see faculty royalty sharing.
Common mistakes
- Charging a normal upfront fee that the startup cannot pay.
- Deferred payments with no long-stop date.
- Mixing up licence equity and incubator equity in one document.
- Exclusive licences with no diligence milestones.
- Letting a founder-inventor negotiate for the institute.
My view: a small royalty with clear milestones serves most institutes better than equity, because few institutes have the staff to manage shareholdings well. I am less certain for software startups, where NISP allows a revenue share and equity may fit investors better; take advice for each case.
For the patents behind these licences, Zernyx IPMS is an IP lifecycle management platform for universities and research institutions, to manage patents, filings and IP portfolios end to end.
Common questions
How much royalty can an Indian institute charge its own startup?
The National Innovation and Startup Policy 2019 says royalties would be no more than 4% of sale price, preferably 1 to 2%, unless the product is pure software, where a revenue share can be agreed. Individual institutes set their own policies within this guidance.
Can a university take equity instead of royalty?
Yes. NISP 2019 says that if the institute takes shares in the company, the shares will be 1% to 4%. Separately, an institute's incubator may take 2% to 9.5% equity in return for services and facilities. Keep the two clearly apart in the documents.
What is a deferred royalty or deferred fee?
A payment the startup owes but pays later, triggered by an event such as a funding round, first sales or a set date. It lets a cash-poor startup take a licence now while the institute keeps a fair price. The trigger and amount must be written into the licence.
Should a university give its startup an exclusive licence?
Often, because investors want exclusivity. Grant it for a defined field and territory, with diligence milestones the startup must meet, and the right to narrow or end exclusivity if it does not. That protects the institute if the startup stalls.